Clinical trials: Retinal Vein Occlusion (RVO)
Macular Edema
Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO).
- Trial name
- NCT03739593
- Testing
- AR-1105-CF1, AR-1105-CF2
- Where
- 11 sites in United States
- Volunteers
- 49 people
- Sponsor
- Aerie Pharmaceuticals
Retinal Vein Occlusion
Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO
Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
- Trial name
- NCT02387788
- Testing
- AKB-9778
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Aerpio Therapeutics
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that…
- Trial name
- NCT07308639
- Testing
- anti-VEGF medication
- Where
- Germany
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Macular Edema, Retinal Vein Occlusion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- Trial name
- BEACON (NCT04592419)
- Testing
- KSI-301, Aflibercept
- Where
- 141 sites in United States, Czechia and 10 more
- Volunteers
- 568 people
- Sponsor
- Kodiak Sciences Inc
Neovascular Age-related Macular Degeneration, Macular Edema
A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO
This is a open label, multicenter, Phase II study to evaluate the usability of the pre-filled syringe (PFS) of SB11 (ranibizumab biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT06176963
- Testing
- SB11 PFS
- Where
- 3 sites in Poland
- Volunteers
- 34 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO
A Trial to Evaluate the Safety and Usability of the SB15 PFS in Trial Participants With AMD, Macular Oedema Secondary to RVO, or Diabetic Macular Oedema
This is an open label, multicenter, Phase II trial to evaluate the safety and usability of the pre-filled syringe (PFS) of SB15 (Aflibercept biosimilar).
- Conditions
- Neovascular Age-related Macular Degeneration, Macular Oedema Secondary to RVO, Diabetic Macular Oedema
- Trial name
- NCT07844343
- Testing
- SB15 PFS
- Where
- 3 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Retinal Vein Occlusion
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent…
- Trial name
- NCT01442064
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Retinal Vein Occlusion, Macular Edema
Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits.
- Trial name
- NCT01411696
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- United States
- Volunteers
- 289 people
- Sponsor
- Allergan
Macular Edema, Retinal Vein Occlusion
Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
This study will evaluate the safety and efficacy of a single intravitreal injection of AGN208397 to treat Macular Edema associated with Retinal Vein Occlusion.
- Trial name
- NCT01027650
- Testing
- AGN208397 intravitreal injection, dexamethasone intravitreal implant
- Where
- 5 sites in United States, Australia and 3 more
- Volunteers
- 121 people
- Sponsor
- Allergan
Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion With Macular Edema
Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO
To determine whether TLC399 (ProDex) provides an ideal, safe, long-acting, dexamethasone sodium phosphate (DSP) delivery system for the treatment of macular edema due to retinal vein occlusion (RVO).
- Trial name
- NCT02006147
- Testing
- TLC399
- Where
- 6 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- Taiwan Liposome Company
Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein…
- Trial name
- RVO in Japan (NCT01377597)
- Testing
- ranibizumab
- Where
- 8 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
A phase 2, multicenter, randomized, active-controlled, masked, parallel arm study designed to evaluate the safety and efficacy of a single suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension, given…
- Trial name
- TANZANITE (NCT02303184)
- Testing
- 4 mg CLS-TA, IVT aflibercept
- Where
- 14 sites in United States
- Volunteers
- 46 people
- Sponsor
- Clearside Biomedical, Inc.
Macular Edema, Diabetic Macular Edema
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Trial name
- NCT02867735
- Testing
- LKA651
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO…
- Trial name
- TOPAZ (NCT03203447)
- Testing
- suprachoroidal CLS-TA, Lucentis or Avastin
- Where
- 92 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- Clearside Biomedical, Inc.
Retinal Vein Occlusion
Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the…
- Trial name
- NCT01580020
- Testing
- RFB002, Dexamethasone
- Where
- 37 sites in Germany
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT05099094
- Testing
- BD311
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to…
- Trial name
- CRUISE (NCT00485836)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 392 people
- Sponsor
- Genentech, Inc.
Macular Edema
A Retrospective Data Collection Study in Patients Receiving Dexamethasone Intravitreal Implant (Ozurdex®) for Macular Oedema Due to Retinal Vein Occlusion (RVO)
This study will use retrospective data to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular oedema due to Retinal Vein Occlusion (RVO).
- Trial name
- NCT01445626
- Testing
- dexamethasone intravitreal implant 0.7 mg
- Where
- Germany
- Volunteers
- 87 people
- Sponsor
- Allergan
Choroidal Neovascularization, Age-related Macular Degeneration
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
This was an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported here) enrolled patients with primary or recurrent Choroidal Neovascularization (CNV)…
- Trial name
- NCT00379795
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 853 people
- Sponsor
- Genentech, Inc.